The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Items 301–400 of 710
Zhao, Y., Tang, L., Shao, J., Chen, D., Jiang, Y., Tang, P., & Wang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1222947 · Cited by 14
Arrarás, J. I., Illarramendi, J. J., Manterola, A., Asín, G., Salgado, E., Arrondo, P., Dominguez, M. A., Arrazubi, V., Martinez, E., Viúdez, A., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02048-4 · Cited by 13
Stephenson, J. J., Gable, J. C., Zincavage, R. M., Price, G. L., Churchill, C., Zhu, E., Stenger, K. B., Singhal, M., Nepal, B., Grabner, M., et al. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s319239 · Cited by 13
Braal, C. L., Westenberg, J. D., Buijs, S. M., Abrams, S., Mulder, T. A. M., van Schaik, R. H. N., Koolen, S. L. W., Jager, A., & Mathijssen, R. H. J. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06643-y · Cited by 13
Feasibility of a Supervised Virtual Exercise Program for Women on Hormone Therapy for Breast Cancer
Myers, S. A., Weller, S., Schwartz, S., Patten, C. L. V., LeVasseur, N., Faulkner, G., & Campbell, K. L. (2022) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000213 · Cited by 13
Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review
Onwusah, D. O., Ojewole, E. B., & Chimbari, M. J. (2023) · JCO Global Oncology · doi:10.1200/go.21.00289 · Cited by 13
Stewart, S.-J., Slodkowska‐Barabasz, J., Hackshaw‐McGeagh, L., Moon, Z., Brett, J., Wells, M., Brown, M. C., Turner, M., Horne, R., Fenlon, D., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.05.007 · Cited by 14
Railton, C., Lupichuk, S., McCormick, J., Zhong, L., Ko, J. J., Walley, B. A., Joy, A. A., & Giese‐Davis, J. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0091 · Cited by 13
Vanderpool, R. C., Swanberg, J. E., & Chambers, M. D. (2013) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2013.046 · Cited by 13
Kesmodel, S. B., Goloubeva, O. G., Rosenblatt, P., Heiss, B. L., Bellavance, E. C., Chumsri, S., Bao, T., Thompson, J. D., Nightingale, G., Tait, N. S., et al. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000314 · Cited by 14
Mullooly, M., & Gierach, G. L. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky072 · Cited by 13
Ettl, J., Anders, S.-I., Hapfelmeier, A., Paepke, S., Noske, A., Weichert, W., Klein, E., & Kiechle, M. B. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05771-4 · Cited by 13
Psychosocial Correlates of Appointment Keeping in Immigrant Cancer Patients
Costas-Muñíz, R., Leng, J. C. F., Diamond, L. C., Aragones, A., Ramirez, J., & Gany, F. M. (2015) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2014.992084 · Cited by 13
Yin, Z., Malin, B., Warner, J. L., Hsueh, P.-Y. S., & Chen, C.-H. (2017) · Proceedings of the International AAAI Conference on Web and Social Media · doi:10.1609/icwsm.v11i1.14892 · Cited by 13
Bright, E. E., & Stanton, A. L. (2018) · Annals of Behavioral Medicine · doi:10.1093/abm/kay094 · Cited by 13
Borm, K. J., Hörner‐Rieber, J., Duma, N. M., Budach, W., Piroth, M. D., Krug, D. A., & Breast Cancer Expert Panel of the German Society of Radiation Oncology DEGRO (2025) · Strahlentherapie und Onkologie · doi:10.1007/s00066-025-02391-2 · Cited by 13
Genovese, C., Garozzo, A., D’Angeli, F., Malfa, G. A., Bellia, F., Tomasello, B., Nicolosi, D., Malaguarnera, R., Ronsisvalle, S., Guadagni, F., et al. (2022) · Cells · doi:10.3390/cells11101696 · Cited by 12
Sung, S., Min, Y. H., Park, S. K., & Lee, S. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844926 · Cited by 12
Gremke, N., Griewing, S., Chaudhari, S., Upadhyaya, S., Nikolov, I., Kostev, K., & Kalder, M. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04376-5 · Cited by 12
Photobiomodulation et troubles vulvovaginaux après traitements anticancéreux
Forret, A., Marès, P., Delacroix, C., Chevallier, T., Potier, H., Fatton, B., Masia, F., Ripart, S., Letouzey, V., de Tayrac, R., et al. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.03.018 · Cited by 12
Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients
He, W., Smedby, K. E. E., Fang, F., Olsson, H., Margolin, S., Hall, P. N., & Czene, K. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx041 · Cited by 12
Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women
Rossi, L., & Pagani, O. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0473-1 · Cited by 12
General Overview and Treatment Recommendations for Young Women with Breast Cancer
Ribnikar, D., Ratoša, I., Perhavec, A., & Amir, E. (2017) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.17002175 · Cited by 13
Peng, N., Yu, M., Yang, G., Fu, Q., Xu, Y.-M., Yu, J., Liu, Q., Li, C., Xu, W.-R., Zhang, Y., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.08.003 · Cited by 13
Park, S., Knobf, M. T., & Jeon, S. (2019) · Journal of Nursing Scholarship · doi:10.1111/jnu.12471 · Cited by 12
Yuan, C., Xie, Z., Bian, J., Huo, J. S., & Daily, K. C. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05591-9 · Cited by 12
Neuner, J. M., Weil, E., Fergestrom, N. M., Stolley, M. R., Kamaraju, S., Oxencis, C. J., Winn, A. N., Laud, P. W., & Flynn, K. E. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.03.001 · Cited by 12
Laplana, M., García-Marqueta, M., Sánchez, J. J., Pérez, E. M., Pérez, H., Martínez-Montesinos, I., Eraso, A., Gutiérrez, P. S., Martín, R., Martín, M. I., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02823-w · Cited by 12
Rosenberg, S. M., Zheng, Y. H., Gelber, S. I., Ruddy, K. J., Poorvu, P. D., Sella, T., Tamimi, R. M., Wassermann, J., Schapira, L., Borges, V. F., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06810-1 · Cited by 13
The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa
Ayeni, O., Chiwambutsa, S., Chen, W. C., Kapungu, N. N., Kanji, C. R., Thelingwani, R. S., Murugan, N., Mathiba, R. M., Phakathi, B., Nietz, S., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06835-6 · Cited by 14
Onwusah, D. O., Ojewole, E. B., Manyangadze, T., & Chimbari, M. J. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s416843 · Cited by 12
Sousa, M. S., Peate, M., Lewis, C. R., Jarvis, S. K., Willis, A. M., Hickey, M., & Friedlander, M. L. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12820 · Cited by 12
Pieters, H. C., Green, E., Khakshooy, S., Sleven, M., & Stanton, A. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210972 · Cited by 13
Anderson, J. N., Krukowski, R. A., Paladino, A. J., Graff, J. C., Schwartzberg, L. S., Curry, A. N., Vidal, G. A., Jones, T. N., Waters, T. M., & Graetz, I. (2020) · Journal of Hospital Management and Health Policy · doi:10.21037/jhmhp-20-103 · Cited by 12
Boudreau, M. W., Mulligan, M. P., Shapiro, D. J., Fan, T. M., & Hergenrother, P. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01730 · Cited by 12
Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer
Neuner, J. M., Fergestrom, N. M., Pezzin, L. E., Laud, P. W., Ruddy, K. J., & Winn, A. N. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06704-2 · Cited by 13
Zeng, E., He, W., Smedby, K. E. E., & Czene, K. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7116 · Cited by 11
Stearns, V., Jegede, O. A., Chang, V. T.-S., Skaar, T. C., Berenberg, J. L., Nand, R., Shafqat, A., Jacobs, N. L., Luginbuhl, W. E., Gilman, P. B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2137 · Cited by 11
Hussain, M., Brezden‐Masley, C., Chia, S., Curigliano, G., Webster, M. A., & Henning, J. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251326710 · Cited by 14
Schwartzberg, B. S., Chin, D. T. H., Dorn, P. L., Herron, D. S., Howell, K. T., Kemmis, T. J., Miller, S. A., Moore, J. A., & Paul, D. (2018) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2018.07.022 · Cited by 11
Adherence to adjuvant hormonal therapy in localised breast cancer
Davies, S., & Voutsadakis, I. A. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13729 · Cited by 11
McGuinness, S., Hughes, L. D., Moss-Morris, R. E., Hunter, M. S., Norton, S., & Moon, Z. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13722 · Cited by 11
Identification of Patients at Very Low Risk of Local Recurrence After Breast-Conserving Surgery
Smith, S. L., Truong, P. T., Lu, L., Lesperance, M., & Olivotto, I. A. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.03.016 · Cited by 11
Patrick, J., Hasse, M. E., Feinglass, J. M., & Khan, S. A. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2017.07.006 · Cited by 12
Lee, Y., Park, Y. R., Lee, J. S., Lee, S. B., Chung, I. Y., Son, B. H., Ahn, S. H., & Lee, J. W. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e14 · Cited by 12
Ku, G. C., Chapdelaine, A. G., Ayrapetov, M. K., & Sun, G. (2022) · Cancers · doi:10.3390/cancers14164027 · Cited by 11
Hall, L. H., Clark, J., Smith, S. G., Graham, C. D., & for the ACTION investigators (2022) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2021.1955318 · Cited by 10
Boukhechba, M., Baee, S., Nobles, A. L., Gong, J., Wells, K., & Barnes, L. E. (2018) · 2018 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI) · doi:10.1109/bhi.2018.8333422 · Cited by 10
Long-Term Follow-Up Care After Treatment for Primary Breast Cancer: Strategies and Considerations
Franzoi, M. A., Janni, W. J., Erdmann-Sager, J., Kline‐Quiroz, C. M., Schäffler, H., Pfister, K., Fazzalari, A., & Vaz-Luís, I. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473472 · Cited by 10
Huiart, L., Ferdynus, C., Dell’Aniello, S., Bakiri, N., Giorgi, R., & Suissa, S. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3631 · Cited by 10
Baglione, A. N., Gong, J., Boukhechba, M., Wells, K. J., & Barnes, L. E. (2020) · IEEE Pervasive Computing · doi:10.1109/mprv.2020.2993993 · Cited by 11
Passardi, A., Foca, F., Caffo, O., Tondini, C. A., Zambelli, A., Vespignani, R., Bartolini, G., Sullo, F. G., Andreis, D., Dianti, M., et al. (2022) · Journal of Medical Internet Research · doi:10.2196/27349 · Cited by 10
Marsden, J. (2022) · Post Reproductive Health · doi:10.1177/20533691221122358 · Cited by 10
Janssen, A. M., Dam, J., Prins, J. B., Buffart, L. M., & de Bruin, M. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13721 · Cited by 10
Rahimi, S., Ononogbu, O., Mohan, A., Moussa, D. N., Abughosh, S., & Trivedi, M. V. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01609-6 · Cited by 10
Green, S. M. C., Hall, L., French, D., Rousseau, N. S., Parbutt, C., Walwyn, R. E. A., & Smith, S. G. (2023) · Annals of Behavioral Medicine · doi:10.1093/abm/kaad037 · Cited by 10
CBD-oil as a potential solution in case of severe tamoxifen-related side effects
Buijs, S. M., Braal, C. L., Buck, S. A. J., van Maanen, N. F., van der Meijden-Erkelens, L. M., van Patot, H. A. K.-T., Hoop, E. O., Saes, L., van den Boogerd, S., Struik, L. E. M., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00570-x · Cited by 10
Yin, Z., Xie, W., & Malin, B. (2017) · PubMed Central · Cited by 10
Bens, A., Langballe, R., Bernstein, J. L., Cronin-Fenton, D. P., Friis, S., & Mellemkjær, L. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1643915 · Cited by 11
Breast Cancer Surgery Decision Role Perceptions and Choice of Surgery
Gutnik, L. A., Allen, C. M., Presson, A. P., & Matsen, C. B. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08485-8 · Cited by 10
Villarreal-Garza, C. M., Mesa-Chávez, F., Ferrigno, A. S., la Garza‐Ramos, C. D., Fonseca, A., Villanueva-Tamez, K., Campos-Salgado, J. Y., Cruz‐Ramos, M., Rodriguez-Gomez, D. O., Ruiz-Cruz, S., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.05.013 · Cited by 10
Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer
Benoit, L., Cambra, C., Rouzier, R., Cottu, P. H., Rodrigues, M. J., Reyal, F., & Bonneau, C. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.09.012 · Cited by 10
Yanez, B. R., Oswald, L. B., Denburg, A. N. V., Baik, S. H., Czech, K. A., Buitrago, D., Maletich, C., Wortman, K., Penedo, F. J., & Victorson, D. E. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100898 · Cited by 10
He, W., Eriksson, L., Törnberg, S., Strand, F., Hall, P. N., & Czene, K. (2019) · BMC Medicine · doi:10.1186/s12916-019-1252-6 · Cited by 10
Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia
Anand, K., & Niravath, P. A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0795-1 · Cited by 10
Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
Uslu, Y., Kocatepe, V., Sezgin, D. S., & Uras, C. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07742-2 · Cited by 11
Interventions to improve oral endocrine therapy adherence in breast cancer patients
Ganna, S., Rahimi, S., Lu, A., LaBorde, K., & Trivedi, M. V. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01513-y · Cited by 9
Turcu-Ştiolică, A., Udriștoiu, I., Subtirelu, M.-S., Gheorman, V., Aldea, M., Dumitrescu, E. A., Volovăț, S. R., Median, D., & Lungulescu, C. V. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1345482 · Cited by 9
Ravix, A., Bandiera, C., Cardoso, E., Lata-Pedreira, A., Chtioui, H., Decosterd, L. A., Wagner, D., Schneider, M. P., Csajka, C., & Guidi, M. (2024) · Cancers · doi:10.3390/cancers16122193 · Cited by 9
Zuo, H., Vaihenberg, E., Singh, A., Bal, G., Bigras, G., Fenton, D. W., King, K., Yuan, Y., & Joseph, K. J. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115665 · Cited by 9
Descriptive analysis of 192 cases of breast cancer occurring before age 40 in Yaounde, Cameroon
Essiben, F., Foumane, P., Meka, E. J., Tchakounté, M., Dohbit, J. S., Nsahlaï, C., Atenguena, E., Njotang, P. N., & Mboudou, E. T. (2017) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20172898 · Cited by 9
Wallwiener, M., Nabieva, N., Feißt, M., Fehm, T. N., Waal, J. D., Rezai, M., Baier, B., Baake, G., Kolberg, H., Guggenberger, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5806-y · Cited by 9
Tan, E. H., Wong, A. L. A., Tan, C. C., Wong, P., Tan, S. H., Ang, L. E. Y., Lim, S. E., Chong, W. Q., Ho, J., Lee, S. C., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06204-9 · Cited by 11
Bluethmann, S. M., Truica, C. I., Klepin, H. D., Olsen, N. J., Sciamanna, C., Chinchilli, V. M., & Schmitz, K. H. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.05.011 · Cited by 9
Self-citationRyu, E., & Ha, S. (2021) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/2347-5625.314610 · Cited by 9
Camejo, N., Castillo, C., Tambasco, C., Strazzarino, N., Requena, N., Peraza, S., Boronat, A., Herrera, G., Esperón, P., Cuello, M., et al. (2023) · World Journal of Oncology · doi:10.14740/wjon1647 · Cited by 9
Taketani, K., Tokunaga, E., Yamashita, N., Tanaka, K., Akiyoshi, S., Okada, S., Ando, K., Kimura, Y., Saeki, H., Oki, E., et al. (2013) · Surgery Today · doi:10.1007/s00595-013-0762-7 · Cited by 10
Hertz, D. L., Speth, K. A., Kidwell, K., Gersch, C. L., Desta, Z., Storniolo, A. M., Stearns, V., Skaar, T. C., Hayes, D. F., Henry, N. L., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4346-x · Cited by 9
Doornik, E. M. V. D. W.-V., Slot, D. E., Burtin, C., & van der Weijden, G. A. (2017) · Physical Therapy · doi:10.1093/ptj/pzx069 · Cited by 9
Patient experience of taking adjuvant endocrine therapy for breast cancer: a tough pill to swallow
Wen, K., Smith, R. F., Padmanabhan, A., & Goldstein, L. J. (2017) · Patient Experience Journal · doi:10.35680/2372-0247.1173 · Cited by 9
Simões, B. M., Kohler, B., Clarke, R. B., Stringer, J., Frazer, L. N., Young, K., Rautemaa‐Richardson, R., Zucchini, G., Armstrong, A. C., & Howell, S. J. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918766189 · Cited by 9
Graham, C. D., Ellison, R., Hall, L. H., Clark, J., McNaught, E., Green, S. M. C., Wilkes, H., Robson, G., Lorentz, I., Holmes, L., et al. (2024) · Psycho-Oncology · doi:10.1002/pon.6349 · Cited by 8
Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana
Wester, J. R., Wagner, R. B., Motladiile, B., Nkele, I., Chinyepi, N., Makhema, M. J., Friebel, T. M., Vuylsteke, P., Lockman, S., Dryden‐Peterson, S., et al. (2024) · JCO Global Oncology · doi:10.1200/go.24.00180 · Cited by 8
Savard, M.-F., Ibrahim, M. F. K., Saunders, D., Pond, G. R., Ng, T., Awan, A. A., Sehdev, S., Alqahtani, N., Vandermeer, L., MacDonald, F., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00762-7 · Cited by 8
Wang, X., Jia, R., Xiang, G., Zhang, D., Wang, Y., & Xu, H. (2025) · Health Science Reports · doi:10.1002/hsr2.70934 · Cited by 8
Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer
Dumas, É., Hamy, A., Wanis, K. N., Jochum, F., Coussy, F., Giacchetti, S., Gaillard, T., Laas, E., Houzard, S., Bihan-Benjamin, C. L., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.50842 · Cited by 9
de Paula, J. C. P., Rocha, V. M. P., Bayer, V. M. L., Ficanha, E. E., & da Silva, E. V. (2021) · Research Society and Development · doi:10.33448/rsd-v10i3.13235 · Cited by 8
Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer
Lambert, L. K., Balneaves, L. G., Howard, A. F., Chia, S., & Gotay, C. C. (2021) · Current Oncology · doi:10.3390/curroncol28020139 · Cited by 8
Cahir, C., Bennett, K., Dombrowski, S. U., Kelly, C. M., Wells, M., Watson, E. K., & Sharp, L. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07658-x · Cited by 8
Borreani, C., Alfieri, S., Infante, G., Miceli, R., Mariani, P., Bosisio, M., Vernieri, C., Bianchi, G., & Capri, G. (2020) · Oncology · doi:10.1159/000509651 · Cited by 8
Zheng, C., & Chagpar, A. B. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06510-w · Cited by 8
Martinez, J. A., Wertheim, B. C., Roe, D. J., Chalasani, P., Cohen, J., Baer, L. N., Chow, H. ‐. S., Stopeck, A., & Thompson, P. A. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06485-0 · Cited by 8
Qin, X., Huckfeldt, P. J., Abraham, J. M., Yee, D., & Virnig, B. A. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac062 · Cited by 8
Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology
Allen, S. G., Speers, C. W., & Jagsi, R. (2022) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2022.01.006 · Cited by 8
Rassy, E., Bardet, A., Bougacha, O., Gantzer, L., Lekens, B., Delaloge, S., André, F., Michiels, S., & Pistilli, B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.44849 · Cited by 8
López, A. M., Pruthi, S., Boughey, J. C., Perloff, M., Hsu, C.-H., Lang, J. E., Ley, M., Frank, D. H., Taverna, J. A., & Chow, H. ‐. S. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0322 · Cited by 9
O’Neill, S. C., Isaacs, C. J., Lynce, F. C., Graham, D. M. A., Chao, C. Y., Sheppard, V. B., Zhou, Y., Liu, C., Selvam, N., Schwartz, M. D., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0837-2 · Cited by 8
Zhou, J., Lei, J., Wang, J., Lian, C., Li, H., Yang, L., & Wu, S. (2020) · Aging · doi:10.18632/aging.103111 · Cited by 8
Cahir, C., Dombrowski, S. U., Kennedy, M. J., Sharp, L., & Bennett, K. (2017) · Psychology and Health · doi:10.1080/08870446.2017.1296151 · Cited by 8
Cruz, A., Rodrigues, A. T., Ferracini, A. C., Stahlschmidt, R., Silva, N., & Mazzola, P. G. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.72397 · Cited by 8
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
